Anti-Human CD1c FITC 100 tests
- Known as:
- Antibody toHuman CD1c fluorecein 100 tests
- Catalog number:
- 11-0015-42
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Human CD1c FITC 100 tests
Related genes to: Anti-Human CD1c FITC 100 tests
- Gene:
- CD1C NIH gene
- Name:
- CD1c molecule
- Previous symbol:
- CD1
- Synonyms:
- -
- Chromosome:
- 1q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 1988-05-11
- Date modifiied:
- 2014-11-19
Related products to: Anti-Human CD1c FITC 100 tests
Related articles to: Anti-Human CD1c FITC 100 tests
- Langerhans cells (LCs) are primary immune sentinels at barrier surfaces, acting as the first line of defence against foreign pathogens. However, their low abundance within the human epidermis severely limits their availability for functional and mechanistic studies. To address this challenge, we sought to provide a versatile experimental framework for generating, identifying, and characterizing distinct subsets of LCs derived from in vitro differentiation of human peripheral monocytes. LCs' heterogeneity has long been considered, with recent studies classifying them into four subsets: effector LCs (LC1) and regulatory LCs (LC2) present at steady state, along with activated LCs (aLC) and migratory LCs (migLC) found during skin inflammation. In this study, LC1, LC2, and aLC/migLC subsets were identified by flow cytometric profiling of CD207, CD1a, CD83, and CD197. LC phenotype was further confirmed by examining HLA-DR, CD14, CD209, CD1b, and CD1c expression. Additionally, the phagocytic capacity of LCs relative to distinct macrophage polarizations was evaluated. From the in vitro-generated LCs, the subsets LC1, LC2, and a joint aLC/migLC cluster were identified. LC1 constituted the predominant population, appearing at higher proportions than both LC2 and the aLC/migLC cluster. The proportions of LC2 and aLC/migLC remained relatively consistent across donors, whereas LC1 abundance showed greater variation, suggesting a higher donor-dependent heterogeneity. Overall, LCs exhibited the lowest phagocytic capacity compared with the different macrophage polarizations. Our study defines LC subsets that can be generated from peripheral monocytes in vitro and provides a framework for deeper exploration of human LC biology, subset heterogeneity, and function in both normal and pathological skin. - Source: PubMed
Publication date: 2026/09/07
Hasterok SylwiaBerggren KlasAf Klinteberg ClaesEriksson HåkanOhlsson LarsGustafsson Anna - Heart transplantation (HT) remains the primary treatment for end-stage heart failure, but graft rejection-including acute cellular rejection (ACR), antibody-mediated rejection (AMR), and chronic rejection such as cardiac allograft vasculopathy (CAV)-significantly impacts long-term patient outcomes. This study investigates the role of circulating plasma extracellular vesicle profiles as potential biomarkers for distinguishing between different rejection types following HT. - Source: PubMed
Aquino ArthurKorneva LubovOsipova MariaBortsova MariaSimonenko MariaSambur DarinaGolovkin IvanKudryavtsev IgorZaikova EkaterinaKostareva AnnaKalinina OlgaFedotov PetrGolovkin Alexey - Tuberculous meningitis (TBM) is a severe central nervous system infection in which dysregulated host inflammation contributes to neurological injury. The cellular organization of the cerebrospinal fluid (CSF) immune microenvironment in TBM, particularly in comparison with other inflammatory meningitis conditions, remains incompletely defined. This study characterized CSF immune-cell heterogeneity in TBM and purulent meningitis (PM) using single-cell transcriptomic profiling. - Source: PubMed
Publication date: 2026/08/13
Hu HaoyangHou LeiWang YanYu ZekaiZhang JiatangYang Fei - Endometriosis (EMS) is a chronic inflammatory disorder involving ectopic endometrial tissue growth. This study investigated IL-33, CD1c+ dendritic cells (DCs) and their co-stimulatory molecules (CD40, CD80, CD86), and IL-17 A in the peritoneal fluid (PF) of EMS patients, and explored their interrelationships. - Source: PubMed
Publication date: 2026/08/13
Yuan WenHuang JiaoHe TaoLi HuanniWu Xianqing - Melanoma, as an immunogenic skin cancer, is an area of great interest in cancer immunotherapy. Immune checkpoint inhibitors (ICIs) have resulted in improved clinical outcomes in selected patients, but resistance or relapsing disease remains a problem. Dendritic cells (DCs) have the potential to enhance antitumor immunity since they are the most potent antigen-presenting cells and can prime and activate tumor-specific T cells. Recent advancements in single-cell technologies have enabled us to characterize tumor-infiltrating DC subsets (conventional type 1 (cDC1s) and cDC2s, plasmacytoid (pDCs), monocyte-derived (moDCs), as well as potentially novel subsets like DC3s) entirely and characterize their distinct roles in promoting melanoma development, evading immune surveillance, and/or their ability to respond to therapy. DCs can capture, process, and present antigens to activate and regulate T-cell-mediated immune responses, with T-cell immunity needed to control melanoma. Consequently, Next-generation DC-based immunotherapy approaches are being examined. These approaches involve vaccines that utilize naturally circulating DC subsets (ie, CD1c⁺ mDCs, activated pDCs) as well as DCs charged with tumor-specific neoantigens or mRNA, and approaches containing toll-like receptor (TLR) ligands, STING pathway agonists, nanoparticles, and oncolytic viruses to enhance DC maturation and antigen presentation. Furthermore, DC will be combined with treatments including ICIs, adoptive T cell therapy, or chemotherapy to induce enhanced synergistic immune reactions. In this review, we summarize the DC subset functions in melanoma, the underlying mechanisms of DC dysfunction in the tumor microenvironment, and the most recent updates on next-generation DC-based therapies. We also highlight the need for clinical translation and determining barriers and challenges in the personalization of melanoma vaccines and even combination treatment with pre-existing therapies that consider the potential of DC biology. - Source: PubMed
Publication date: 2026/07/29
Rodrigues Donisha SonalSaeed Bahaa IbrahimAlkhathami Ali GKareem A KTillyashaykhov MirzagalebAl-Khafaji Zahraa AbbasAl-Mashhadani Zuhair IKadhum Wesam RBokhoor Sami NajafMustafa Yasser Fakri